Published in J Nucl Med on January 01, 2000
Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging (2006) 1.50
Neuromodulation of reward-based learning and decision making in human aging. Ann N Y Acad Sci (2011) 1.34
Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder. Biol Psychiatry (2013) 1.07
Ontogeny and regulation of the serotonin transporter: providing insights into human disorders. Pharmacol Ther (2011) 0.96
Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur Neuropsychopharmacol (2010) 0.93
Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging (2009) 0.93
Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) (2004) 0.93
Parkinson's disease as a result of aging. Aging Cell (2015) 0.92
How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry (2005) 0.89
Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM. J Neural Transm (Vienna) (2006) 0.88
Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD). Eur Arch Psychiatry Clin Neurosci (2004) 0.85
Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging (2014) 0.84
Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom. Eur J Nucl Med Mol Imaging (2006) 0.83
Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. J Neural Transm (Vienna) (2008) 0.83
Is correction for age necessary in neuroimaging studies of the central serotonin transporter? Eur J Nucl Med Mol Imaging (2003) 0.83
Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease. Nucl Med Mol Imaging (2011) 0.82
Brain regional alpha-[11C]methyl-L-tryptophan trapping, used as an index of 5-HT synthesis, in healthy adults: absence of an age effect. Eur J Nucl Med Mol Imaging (2007) 0.79
Loudness dependence of auditory evoked potentials (LDAEP) correlates with the availability of dopamine transporters and serotonin transporters in healthy volunteers-a two isotopes SPECT study. Psychopharmacology (Berl) (2010) 0.79
A new model for separation between brain dopamine and serotonin transporters in 123I-beta-CIT SPECT measurements: normal values and sex and age dependence. Eur J Nucl Med Mol Imaging (2004) 0.78
Treatment improves serotonin transporter binding and reduces binge eating. Psychopharmacology (Berl) (2003) 0.77
The effects of ecstasy (MDMA) on brain serotonin transporters are dependent on age-of-first exposure in recreational users and animals. PLoS One (2012) 0.77
The Role of the Serotonergic System in REM Sleep Behavior Disorder. Sleep (2015) 0.76
Increased Brainstem Serotonergic Transporter Availability in Adult Migraineurs: an [(18)F]FP-CIT PET Imaging Pilot Study. Nucl Med Mol Imaging (2015) 0.76
Sleep microstructure and neurodegeneration as measured by [123I]beta-CIT SPECT in treated patients with Parkinson's disease. J Neurol (2004) 0.76
SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias. EJNMMI Res (2013) 0.75
Serotonin transporter availability in early stage Parkinson's disease and multiple system atrophy. ISRN Neurol (2014) 0.75
[123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials. Eur Arch Psychiatry Clin Neurosci (2007) 0.75
Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [123I]beta-CIT SPECT analysis. Eur J Nucl Med Mol Imaging (2006) 0.75
Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging. Neuroimage Clin (2017) 0.75
Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand (2004) 2.52
Suicidal tendencies as a complication of light therapy for seasonal affective disorder: a report of three cases. J Clin Psychiatry (1997) 2.17
EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging (2006) 1.79
Dopamine transporter binding in Gilles de la Tourette syndrome. J Neurol (2000) 1.79
Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med (1997) 1.44
Lymphoscintigraphy with 123I-labelled epidermal growth factor. Lancet (1991) 1.37
Initial experience with technetium-99m HM-PAO brain SPECT. J Nucl Med (1987) 1.30
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance. Kidney Int (1988) 1.27
Fatal familial insomnia: a new Austrian family. Brain (1999) 1.24
Topographic distribution of sleep spindles in young healthy subjects. J Sleep Res (1997) 1.22
T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant (2000) 1.17
Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. Psychol Med (1998) 1.15
Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med (1994) 1.15
Familial hemiplegic migraine: follow-up findings of diffusion-weighted magnetic resonance imaging (MRI), perfusion-MRI and [99mTc] HMPAO-SPECT in a patient with prolonged hemiplegic aura. Cephalalgia (2004) 1.13
Central nervous system function after cardiopulmonary bypass. Eur Heart J (1993) 1.13
Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg (2007) 1.07
Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord (1998) 1.07
[123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm (Vienna) (1998) 1.07
Residence under an airport landing pattern as a factor in teratism. Arch Environ Health (1978) 1.06
[123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Biol Psychiatry (2001) 1.05
Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl (1997) 1.01
Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. Q J Nucl Med Mol Imaging (2004) 1.00
A new algorithm for treating schizophrenia. Psychopharmacol Bull (1998) 0.99
No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry (2001) 0.99
EFNS guideline on neuroimaging in acute stroke. Report of an EFNS task force. Eur J Neurol (2006) 0.99
[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord (2000) 0.98
European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG. Eur J Nucl Med Mol Imaging (2002) 0.97
The activity of the sympathetic nervous system following severe head injury. Intensive Care Med (1980) 0.97
Expression of GABA(A) receptor subunits in the hippocampus of the rat after kainic acid-induced seizures. Epilepsy Res (1998) 0.97
The effects of light therapy on mini-mental state examination scores in demented patients. Biol Psychiatry (2001) 0.97
A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf (1997) 0.97
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab (1991) 0.97
Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res (1994) 0.96
European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. Eur J Nucl Med Mol Imaging (2002) 0.95
Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med (1997) 0.94
A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Mol Psychiatry (2003) 0.94
Excessive daytime sleepiness in patients suffering from different levels of obstructive sleep apnoea syndrome. J Sleep Res (2000) 0.93
Aspects of 6-[18F]fluoro-L-DOPA preparation: precursor synthesis, preparative HPLC purification and determination of radiochemical purity. Nucl Med Biol (2002) 0.93
Low frontal electroencephalographic coherence in neuroleptic-free schizophrenic patients. Biol Psychiatry (1998) 0.92
Adult coeliac disease and brainstem encephalitis. J Neurol Neurosurg Psychiatry (1988) 0.92
Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin (2008) 0.91
[123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry (2000) 0.91
Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med (2001) 0.91
Stenting of stenotic mesenteric arteries for symptomatic chronic mesenteric ischemia. Vasa (2012) 0.90
SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol (2000) 0.90
Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer (2001) 0.90
Autologous low-density lipoprotein labelling allows characterization of human atherosclerotic lesions in vivo as to presence of foam cells and endothelial coverage. Eur J Nucl Med (1991) 0.90
Influence of bilateral Stn-stimulation on psychiatric symptoms and psychosocial functioning in patients with Parkinson's disease. J Neural Transm (Vienna) (2005) 0.89
SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect (1993) 0.89
Imaging of human atherosclerotic lesions using 123I-low-density lipoprotein. Eur J Nucl Med (1986) 0.89
SPECT and MR imaging in herpes simplex encephalitis. J Comput Assist Tomogr (1991) 0.89
Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med (2001) 0.89
Carbohydrate-deficient transferrin as a screening marker for drinking in a general hospital population. Alcohol Alcohol (1996) 0.88
Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des (2002) 0.88
Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol (2003) 0.88
Hypertrophic chronic pachymeningitis as a localized immune process in the craniocervical region. Neurology (2001) 0.88
D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab (1995) 0.87
Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med (1995) 0.87
beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect (1995) 0.86
Linking in vivo brain serotonin type 1B receptor density to phenotypic heterogeneity of posttraumatic stress symptomatology. Mol Psychiatry (2012) 0.86
In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) (2006) 0.86
Dopamine depletion results in increased neostriatal D(2), but not D(1), receptor binding in humans. Mol Psychiatry (2002) 0.86
Normal IPT and IBZM SPECT in drug naive and levodopa-treated idiopathic restless legs syndrome. Neurology (2002) 0.86
Neurochemical aspects of the Rett syndrome. Brain Dev (1985) 0.85
The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality. Psychol Med (2003) 0.85
Monorhinal odor identification and depression scores in patients with seasonal affective disorder. J Affect Disord (1999) 0.85
Inverse relation between stimulus intensity and seizure duration: implications for ECT procedure. J ECT (2001) 0.85
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med (1998) 0.85
Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapy. Arch Gen Psychiatry (1997) 0.84
Quantification of regional cerebral blood flow with IMP-SPECT. Reproducibility and clinical relevance of flow values. Stroke (1989) 0.84
Effect of calculation stress on hemodynamics and plasma catecholamines before and after beta-blockade with propranolol (Inderal) and mepindolol sulfate (Corindolan). Eur J Clin Pharmacol (1979) 0.84
Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med (1998) 0.84
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology (1999) 0.84